189 related articles for article (PubMed ID: 34601284)
21. [Comparison of VEGF, IL-8 and beta-FGF concentrations in the serum and ascites of patients with ovarian cancer].
Sadłecki P; Walentowicz-Sadłecka M; Szymański W; Grabiec M
Ginekol Pol; 2011 Jul; 82(7):498-502. PubMed ID: 21913426
[TBL] [Abstract][Full Text] [Related]
22. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.
Hazelton D; Nicosia RF; Nicosia SV
Clin Cancer Res; 1999 Apr; 5(4):823-9. PubMed ID: 10213218
[TBL] [Abstract][Full Text] [Related]
23. Cell adhesion molecule profiles, proliferation activity and p53 expression in advanced epithelial ovarian cancer induced malignant ascites-Correlation of tissue microarray and cytology microarray.
Toth L; Nagy B; Mehes G; Laszlo E; Molnar PP; Poka R; Hernadi Z
Pathol Res Pract; 2018 Jul; 214(7):978-985. PubMed ID: 29801775
[TBL] [Abstract][Full Text] [Related]
24. Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer.
Liu CD; Tilch L; Kwan D; McFadden DW
J Surg Res; 2002 Jan; 102(1):31-4. PubMed ID: 11792148
[TBL] [Abstract][Full Text] [Related]
25. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels.
Yamamoto S; Konishi I; Mandai M; Kuroda H; Komatsu T; Nanbu K; Sakahara H; Mori T
Br J Cancer; 1997; 76(9):1221-7. PubMed ID: 9365173
[TBL] [Abstract][Full Text] [Related]
26. Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model.
Akutagawa N; Nishikawa A; Iwasaki M; Fujimoto T; Teramoto M; Kitajima Y; Endo T; Shibuya M; Kudo R
Jpn J Cancer Res; 2002 Jun; 93(6):644-51. PubMed ID: 12079512
[TBL] [Abstract][Full Text] [Related]
27. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.
Rizk B; Aboulghar M; Smitz J; Ron-El R
Hum Reprod Update; 1997; 3(3):255-66. PubMed ID: 9322101
[TBL] [Abstract][Full Text] [Related]
28. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
[TBL] [Abstract][Full Text] [Related]
29. Biochemical composition of malignant ascites determines high aggressiveness of undifferentiated ovarian tumors.
Mikuła-Pietrasik J; Uruski P; Szubert S; Moszyński R; Szpurek D; Sajdak S; Tykarski A; Książek K
Med Oncol; 2016 Aug; 33(8):94. PubMed ID: 27431203
[TBL] [Abstract][Full Text] [Related]
30. The clinical significance of vascular endothelial growth factor in malignant ascites.
Zhan N; Dong WG; Wang J
Tumour Biol; 2016 Mar; 37(3):3719-25. PubMed ID: 26462841
[TBL] [Abstract][Full Text] [Related]
31. A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites.
Abdel-Razik A; Mousa N; Elalfy H; Sheta TF; Awad M; Abdelsalam M; Elhelaly R; Elzehery R; Gouda NS; Eldars W
J Gastrointest Cancer; 2017 Mar; 48(1):50-57. PubMed ID: 27614744
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
Hu L; Hofmann J; Zaloudek C; Ferrara N; Hamilton T; Jaffe RB
Am J Pathol; 2002 Nov; 161(5):1917-24. PubMed ID: 12414537
[TBL] [Abstract][Full Text] [Related]
33. Stem-like tumor cells and proinflammatory cytokines in the ascitic fluid of ovarian cancer patients.
Gening SO; Abakumova TV; Antoneeva II; Rizvanov AA; Gening TP; Gafurbaeva DU
Klin Lab Diagn; 2021 May; 66(5):297-303. PubMed ID: 34047516
[TBL] [Abstract][Full Text] [Related]
34. Normalization of the ovarian cancer microenvironment by SPARC.
Said N; Socha MJ; Olearczyk JJ; Elmarakby AA; Imig JD; Motamed K
Mol Cancer Res; 2007 Oct; 5(10):1015-30. PubMed ID: 17951402
[TBL] [Abstract][Full Text] [Related]
35. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer.
Moradi MM; Carson LF; Weinberg B; Haney AF; Twiggs LB; Ramakrishnan S
Cancer; 1993 Oct; 72(8):2433-40. PubMed ID: 8402460
[TBL] [Abstract][Full Text] [Related]
36. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody.
Luo JC; Toyoda M; Shibuya M
Cancer Res; 1998 Jun; 58(12):2594-600. PubMed ID: 9635584
[TBL] [Abstract][Full Text] [Related]
37. VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors.
Wang J; Luo F; Lu JJ; Chen PK; Liu P; Zheng W
Int J Cancer; 2002 Jan; 97(2):163-7. PubMed ID: 11774259
[TBL] [Abstract][Full Text] [Related]
38. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.
Sopo M; Anttila M; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Sallinen H
BMC Cancer; 2019 Jun; 19(1):584. PubMed ID: 31200683
[TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma.
Harlozinska A; Sedlaczek P; Kulpa J; Grybos M; Wójcik E; Van Dalen A; Einarsson R
Anticancer Res; 2004; 24(2C):1149-57. PubMed ID: 15154640
[TBL] [Abstract][Full Text] [Related]
40. Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions.
Matte I; Legault CM; Garde-Granger P; Laplante C; Bessette P; Rancourt C; Piché A
Clin Exp Metastasis; 2016 Dec; 33(8):839-852. PubMed ID: 27612856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
